NATCO Pharma Ltd reported a 37.75 per cent decline in consolidated net profit to ₹132.4 crore for Q3 FY2025, down from ₹212.7 crore in the same quarter last year. The company’s shares plummeted 17.28 per cent to ₹1,008.25 on the NSE, touching a 52-week low of ₹829.60.
The pharmaceutical company’s consolidated revenue from operations fell 37.4 per cent to ₹474.8 crore, compared to ₹758.6 crore in Q3 FY2024. EBITDA witnessed a sharp decline of 85.5 per cent to ₹38.8 crore, with margins contracting by 2,717 basis points to 8.2 per cent.
- Read also: Jubilant FoodWorks Q3 net ₹43.2 crore, revenue surges 56%
The earnings downturn was primarily attributed to weak formulation exports, which decreased to ₹285.8 crore from ₹605.6 crore year-over-year. Domestic formulation sales also dipped to ₹96.1 crore from ₹99.4 crore in the corresponding period.
Despite reduced total expenses at ₹487.4 crore compared to ₹539.3 crore last year, the company’s performance remained under pressure due to weak revenue generation.
Separately, the board declared a third interim dividend of ₹1.50 per equity share for FY2024-25, with February 18, 2025, set as the record date. The dividend payment is scheduled to commence from February 28, 2025.
Rewrite this news article and keep the same structure, information and length.
